24059-83-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Methoxypicolinic acid methyl ester is used as a key intermediate in the synthesis of drug molecules for its potential role in developing antiviral and antitumor agents. Its chemical properties allow for the creation of therapeutic compounds that can target specific diseases and conditions.
Used in Agricultural Chemistry:
In the agricultural sector, 3-Methoxypicolinic acid methyl ester is utilized as a precursor in the development of agrochemicals. Its application aids in enhancing crop protection and management strategies by contributing to the production of effective and targeted pesticides or other agricultural products.
Used in Organic Synthesis:
3-Methoxypicolinic acid methyl ester is employed as a valuable precursor in organic synthesis, enabling the creation of diverse chemical compounds for various applications. Its reactivity and functional groups make it a suitable candidate for use in the production of specialty chemicals, materials, and other organic compounds.

InChI:InChI=1/C8H9NO3/c1-11-6-4-3-5-9-7(6)8(10)12-2/h3-5H,1-2H3

Upstream product

• 874-24-8 3-hydroxypyridine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 62733-99-7 methyl 3-hydroxypicolinate 
• 67-56-1 methanol 
• 16478-52-7 3-methoxypyridine-2-carboxylic acid 

Downstream Products

• 16478-52-7 3-methoxypyridine-2-carboxylic acid 
• 884501-76-2 1-(4-methoxyphenyl)-3-(3-methoxypyridin-2-yl)propane-1,3-dione 
• 1349179-60-7 C₁₈H₁₈BrF₂N₃O₄S 
• 945954-94-9 methyl 6-bromo-3-methoxypyridine-2-carboxylate 
• 884500-73-6 2-(4-hydroxyphenyl)-4H-pyrano[3,2-b]pyridin-4-one 

Relevant academic research and scientific papers

POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER

Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

Pyridine - 2 - amide compound and its preparation method, its pharmaceutical composition and use thereof

The invention relates to a pyridine-2-amide compound shown as a general formula I as well as a preparation method, a pharmaceutical composition and use thereof. The compound as an integrase inhibitor is used for preparing medicines for treating diseases mediated by various vetrovirus integrases including HIV-1 (Human Immunodeficiency Virus-1) integrase.

RORγ MODULATORS

The invention provides an RORγ receptor agonist comprising a compound of formula (I), wherein the variables are as defined herein. These compounds are analogous to known RORγ receptor antagonists. The invention further provides a method of activating -the nuclear receptor RORγ, comprising -contacting the RORγ with an effective amount or concentration of a compound of the invention; and a method of treating cancer in a patient, comprising administering to the patient an effective dose of a compound of the invention.

Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction

Currently, three HIV-1 integrase (IN) active site-directed inhibitors are in clinical use for the treatment of HIV infection. However, emergence of drug resistance mutations have limited the promise of a long-term cure. As an alternative, allosteric inhibition of IN activity has drawn great attention and several of such inhibitors are under early stage clinical development. Specifically, inhibitors of IN and the cellular cofactor LEDGF/p75 remarkably diminish proviral integration in cells and deliver a potent reduction in viral replicative capacity. Distinct from the extensively studied 2-(quinolin-3-yl) acetic acid or 1H-indol-3-yl-2-hydroxy-4-oxobut-2-enoic acid chemotypes, this study discloses a new class of selective IN-LEDGF/p75 inhibitors without the carboxylic acid functionality. More significantly, 3-hydroxypicolinamides also show low micromolar inhibition against IN dimerization, providing novel dual IN inhibitors with in vitro therapeutically selective antiviral effect for further development. Finally, our shape-based ROCS pharmacophore model of the 3-hydroxypicolinamide class of compounds provides a new insight into the binding mode of these novel IN-LEDGF/p75 inhibitors.

N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) Agonists

The nuclear retinoic acid receptor-related orphan receptor γ (RORγ; NR1F3) is a key regulator of inflammatory gene programs involved in T helper 17 (TH17) cell proliferation. As such, synthetic small-molecule repressors (inverse agonists) targeting RORγ have been extensively studied for their potential as therapeutic agents for various autoimmune diseases. Alternatively, enhancing TH17 cell proliferation through activation (agonism) of RORγ may boost an immune response, thereby offering a potentially new approach in cancer immunotherapy. Herein we describe the development of N-arylsulfonyl indolines as RORγ agonists. Structure–activity studies reveal a critical linker region in these molecules as the major determinant for agonism. Hydrogen/deuterium exchange coupled to mass spectrometry (HDX-MS) analysis of RORγ–ligand complexes help rationalize the observed results.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer as well as sepsis

Identification of a novel RAMP-independent CGRP receptor antagonist

Identification of an HIV integrase inhibitor with micromolar affinity for the CGRP receptor led to the discovery of a series of structurally novel CGRP receptor antagonists. Optimization of this series produced compound 16, a low-molecular weight CGRP rec

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Inhibitors of type I MetAPs containing pyridine-2-carboxylic acid thiazol-2-ylamide. Part 1: SAR studies on the determination of the key scaffold

Systematic SAR studies on the HTS hit pyridine-2-carboxylic acid thiazol-2-ylamide (PACT) analogues revealed that the scaffold of PCAT is indispensable for the inhibition of type I MetAP. For effective inhibition of the enzyme, the most suitable position to modify is the 3-position of the pyridine ring of PCAT, and the best substituents are those containing O or N atoms connected directly with the pyridine ring. These findings provide useful information for the design and discovery of more potent inhibitors of type I MetAPs.